Lisanti Capital Growth LLC Has $5.37 Million Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Lisanti Capital Growth LLC lifted its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 143.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 96,935 shares of the company’s stock after acquiring an additional 57,090 shares during the quarter. Lisanti Capital Growth LLC’s holdings in Tarsus Pharmaceuticals were worth $5,367,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. JPMorgan Chase & Co. lifted its holdings in Tarsus Pharmaceuticals by 2,088.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock worth $14,477,000 after buying an additional 420,057 shares during the period. Creative Planning acquired a new position in Tarsus Pharmaceuticals during the 3rd quarter worth about $362,000. Vestal Point Capital LP acquired a new position in Tarsus Pharmaceuticals during the 3rd quarter worth about $7,565,000. Jennison Associates LLC lifted its holdings in Tarsus Pharmaceuticals by 14.8% during the 4th quarter. Jennison Associates LLC now owns 2,500,132 shares of the company’s stock worth $138,432,000 after buying an additional 321,552 shares during the period. Finally, Verition Fund Management LLC acquired a new position in Tarsus Pharmaceuticals during the 3rd quarter worth about $763,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on TARS shares. Guggenheim reaffirmed a “buy” rating and set a $78.00 target price (up from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. Jefferies Financial Group lifted their target price on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday. Barclays cut their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Oppenheimer boosted their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. Finally, The Goldman Sachs Group boosted their price objective on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research note on Friday, November 15th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $63.67.

Tarsus Pharmaceuticals Stock Down 2.2 %

Shares of NASDAQ:TARS opened at $43.57 on Friday. The company has a market capitalization of $1.67 billion, a price-to-earnings ratio of -11.44 and a beta of 1.05. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The business’s 50-day moving average is $50.14 and its 200-day moving average is $43.61. Tarsus Pharmaceuticals, Inc. has a 1 year low of $20.08 and a 1 year high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its earnings results on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The business had revenue of $66.41 million during the quarter, compared to analyst estimates of $58.80 million. Equities research analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.